NHL Completed Phase 2 Trials for Bendamustine (DB06769)

Also known as: Lymphomas: Non-Hodgkin / Non Hodgkin´s Lymphomas / Lymphoma, Non-Hodgkin (NHL) / NHL - Non-Hodgkin's Lymphoma / NHL (Non-Hodgkin Lymphoma) / Lymphoma,Non-Hodgkin / Non-Hodgkin's Disease / Lymphoma, Non-Hodgkin;Hodgkin Disease / Non Hodgkin Lymphoma / Non Hodgkin's Lymphoma / Lymphoma, Non Hodgkin / Non Hodgkin Lymphoma (NHL) / Non-Hodgkin / Non-Hodgkin's Lymphomas / Non-Hodgkin Lymphoma / Non-Hodgkin Lympoma / Non-Hodgkins Lymphoma (NHL) / Non-Hodgkin-Lymphoma / Lymphoma, Non-Hodgkin's / Non Hodgkins Lymphoma / Non-Hodgkin Lymphomas / Lymphoma, Non-Hodgkin / Non-Hodgkin's Lymphoma(NHL) / Non-Hodgkin's Lymphoma (NHL) / Lymphoma. Non-Hodgkin / Non-Hodgkin's Lymphoma / Non-Hodgkins Lymphoma / Lymphoma Non-Hodgkin / Non-Hodgkins's Lymphoma / Non-Hodgkin’s lymphoma / Lymphoma, Non-Hodgkins / Non-Hodgkins / Non-Hodgkin Lymphoma (NHL) / Non-Hodgkin's Lymphoma or Hodgkin's Disease / Lymphoma NOS / Histiocytosis X / Non-Hodgkin's lymphoma NOS / Lymphoma (non-Hodgkin's)

DBCOND0035368 (NHL)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01294579Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)Treatment
NCT01108341Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)Treatment
NCT01133158R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical TrialTreatment
NCT01929265A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's LymphomaTreatment
NCT00069758Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's LymphomaTreatment
NCT00076349SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)Treatment
NCT00547534Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's LymphomaTreatment
NCT00612183Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell LymphomaTreatment
NCT01118845Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell LymphomaTreatment